ClinicalTrials.gov
public full text
Public Domain
Role of FDG PET, Immune and Hypoxic Marker in NSCLC
This is a retrospective study that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of maximum 130 patients with NSCLC treated with surgery with radical intent at our center.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy#905308
- Phase II Trial of Continuation Therapy in Advanced NSCLC#683088
- Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy#432899
- Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC#878612
- Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction#184871
Record · ID 1032036
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive